NATCO PHARMA
|
|
BOM : 524816     NSE : NATCOPHARM     | |
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Good [Stock is Cheap] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : None or < 25% |
Jan 15,2025 |
Price(EOD): ₹ 1,220.60
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 21,860.95 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
NATCO PHARMA | -5.3% | -14.2% | 48.1% |
SUN PHARMACEUTICAL INDUSTRIES | -3.8% | -3% | 34.3% |
CIPLA | -2.8% | -0.1% | 9.3% |
DR REDDYS LABORATORIES | -2.4% | 5.5% | 17.5% |
ZYDUS LIFESCIENCES | -2.4% | -0.3% | 42.1% |
DIVIS LABORATORIES | 0.9% | 0.4% | 53.5% |
MANKIND PHARMA | -8.3% | -3.6% | 20.4% |
TORRENT PHARMACEUTICALS | -3.3% | -4.4% | 31.8% |
LUPIN | -5.5% | 3.2% | 54% |
FUNDAMENTAL ANALYSIS OF NATCO PHARMA
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF NATCO PHARMA
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
11.25
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 1,944.00 Cr
[Latest Qtr - Sep2024 - Consolidated Results ] 3.74
P/B Calculated based on Book Value of Rs 5,853.10 Cr
[Latest Year - Mar2024 - Consolidated Results ] 4.79
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 4,560.60 Cr
[Latest Qtr - Sep2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
12% -53% -51% |
SHARE PRICE MOMENTUM OF NATCO PHARMA
NATCO PHARMA vs SENSEX
DEBT OF NATCO PHARMA
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.06 0.03 0.09 0.06 |
0.06 0.03 0.09 0.06 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF NATCO PHARMA
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF NATCO PHARMA
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
0.62% -0.06% 1.82% 1.2% |
32.94% 75.61% 86.12% 83.33% |
QtrlyTrend |
6 | |
Latest Qtr: Sep2024 | ||
Quarterly Result Analysis → |
NATCO PHARMA related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE ALLCAP | -0.3% | -3.5% | 35.8% |
S&P BSE 500 | -3.1% | -7.8% | 9.8% |
S&P BSE 400 MIDSMALLCAP | -4.9% | -9.2% | 14.9% |
S&P BSE SMALLCAP SELECT INDEX | -5.1% | -10.4% | 13.2% |
S&P BSE 250 SMALLCAP | -5.2% | -9.7% | 13.3% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY 500 | -3.1% | -7.7% | 10.4% |
NIFTY500 MULTICAP 50:25:25 | -3.6% | -8.1% | 11.9% |
NIFTY PHARMA | -4.5% | -0.8% | 26.3% |
NIFTY MID SMALL400 | -4.7% | -8.7% | 14.6% |
NIFTY SMALLCAP 50 | -4.8% | -11.3% | 13.9% |
You may also like the below Video Courses
FAQ about NATCO PHARMA
Is NATCO PHARMA good for long term investment?
As on Jan 15,2025, the Fundamentals of NATCO PHARMA look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of NATCO PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is NATCO PHARMA UnderValued or OverValued?
As on Jan 15,2025, NATCO PHARMA is Under Valued based on the estimates of intrinsic value and hence may be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of NATCO PHARMA ?
As on Jan 15,2025, the Intrinsic Value of NATCO PHARMA is Rs. 2,508.51 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 1,091.90
Fair Value [Median EV / Sales Model] : Rs. 2,572.26
Fair Value [Median Price / Sales Model] : Rs. 2,508.51
Estimated Median Fair Value of NATCO PHARMA : Rs. 2,508.51
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.